PharVision Advisers’s Adtran ADTN Stock Holding History

PharVision Advisers’s Portfolio ADTN Stock Details ADTN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-23,600	Closed	-$221K	–	676
2025 Q3	$221K	Buy	+23,600	New	+$220K	0.12%	423

Other funds holding ADTN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DnB Asset Management Oslo, Norway $28B AUM 26% 1-Year Est. Return

DCM

Divisar Capital Management San Francisco, California $392M AUM 108.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NIM

Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return

PharVision Advisers's ADTN Position: Q4 2025 in Review

PharVision Advisers sold out of Adtran (ADTN) in Q4 2025, closing a stake of 23,600 shares — an estimated $221K sold.

PharVision Advisers first reported a position in ADTN in Q3 2025 and held it in 1 quarter. The position peaked at $221K in Q3 2025. 213 funds tracked by Wall St. Rank hold ADTN as of Q4 2025.

PharVision Advisers reported no remaining Adtran position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 23,600 Adtran shares in Q4 2025, an estimated $221K.
PharVision Advisers first reported a position in Adtran in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Adtran position peaked at $221K in Q3 2025.
213 funds tracked by Wall St. Rank held Adtran as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.